Core Viewpoint - The announcement details the lifting of the lock-up period for certain shareholders of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., allowing for the circulation of previously restricted shares after fulfilling specific commitments [1][2]. Group 1: Share Issuance and Lock-up Period - The company issued 27,041,667 shares during its initial public offering (IPO) on December 20, 2021, resulting in a total share capital of 81,125,000 shares before the IPO and 108,166,667 shares after [1]. - The lock-up period for the shares was initially set at 36 months from the IPO date, which has been extended by an additional 6 months due to the stock price falling below the IPO price for 20 consecutive trading days [15]. Group 2: Shareholder Commitments - Shareholders applying for the lifting of the lock-up include Shao Chunneng, Lou Jinfang, You Minwei, and several investment management partnerships, all of whom have committed to not transferring their shares for 36 months post-IPO [2][3]. - After the lock-up period, shareholders are required to disclose control arrangements and can only sell up to 25% of their shares annually while adhering to specific pricing conditions [3][6]. Group 3: Compliance and Oversight - The company will ensure that shareholders comply with relevant regulations and commitments regarding share sales, including the "Interim Measures for the Management of Shareholder Share Reduction" [16]. - The company’s board will monitor compliance and report on shareholder adherence to commitments in regular disclosures [16]. Group 4: Changes in Share Capital Structure - As of the announcement date, the total share capital stands at 109,228,284 shares, with 39,600,000 shares still under lock-up [2][17]. - The lifting of the lock-up will not change the overall share capital structure, maintaining the total at 109,228,284 shares [17]. Group 5: Underwriting and Verification - The underwriting institution has verified that the application for lifting the lock-up aligns with regulatory requirements and that shareholders have adhered to their commitments made during the IPO [17][18].

证券代码：301096 证券简称：百诚医药 公告编号：2025-030 杭州百诚医药科技股份有限公司 关于首次公开发行前已发行部分股份上市流通的提示性公告 2023 年 11 月 2 日，2022 年限制性股票激励计划首次及预留部分第一个归属 期归属结果暨股份上市，上述归属登记完成后，公司股份总数由 108,166,667 股 增加至 108,919,903 股。具体详见公司于 2023 年 11 月 1 日披露于巨潮资讯网 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、本次解除限售的股份为杭州百诚医药科技股份有限公司（以下简称"公 司"或"发行人"或"百诚医药"）首次公开发行前已发行部分股份。 2、本次解除限售的股份数量为 39,600,000 股，占公司总股本的 36.2543%， 本次解除限售股东户数共计 6 户，限售期为自公司股票上市之日起 42 个月。 3、本次解除限售的股份上市流通日期为 2025 年 6 月 20 日（星期五）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理 ...

国金证券股份有限公司 关于杭州百诚医药科技股份有限公司 首次公开发行前已发行部分股份上市流通的核查意见 国金证券股份有限公司（以下简称"保荐机构"）为杭州百诚医药科技股份 有限公司（以下简称"百诚医药"或"公司"）首次公开发行股票并在创业板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等规则的要求，对百诚医药首次公开发行前已发行部分股份上 市流通事项进行了审慎核查，核查情况及核查意见如下： 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意杭州百诚医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2021]3566 号）核准，同意公司首次公开 发行股票的注册申请，并经深圳证券交易所同意，公司首次向社会公众公开发行 人民币普通股（A 股）股票 27,041,667 股，于 2021 年 12 月 20 日在深圳证券交 易所上市交易。 公司首次公开发行前总股本为 81,125,000 股，首次公开发行后总股本为 108,166,667 ...

Core Viewpoint - The controlling shareholder of Baicheng Pharmaceutical (301096), Lou Jinfang, plans to increase his stake in the company by investing between 50 million and 100 million yuan within six months, with a maximum purchase price of 60 yuan per share [1] Group 1 - The planned share buyback will not exceed 2.00% of the company's total share capital [1] - The funding for the share purchase will come from personal or self-raised funds [1] - The implementation of the buyback plan may face risks due to changes in the capital market, which could affect the expected outcomes [1]

关于控股股东增持公司股份计划的公告 公司控股股东楼金芳女士保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、杭州百诚医药科技股份有限公司（以下简称"公司"）于近日收到控股股 东楼金芳女士出具的《关于股份增持计划的告知函》，楼金芳女士基于对公司长 期投资价值的认可以及未来持续稳定发展的信心，计划自本公告披露之日起 6 个 月内，通过集中竞价交易方式增持公司股份，累计增持金额不低于人民币 5,000 万元且不超过人民币 10,000 万元。本次累计增持比例不超过公司总股本的 2.00%， 不触及要约收购。 2、增持计划实施可能存在因资本市场发生变化等因素或目前尚无法预判的 其他风险因素，导致增持计划的实施无法达到预期。如增持计划实施过程中出现 上述风险情形，公司将及时履行信息披露义务。敬请广大投资者注意投资风险。 一、计划增持主体的基本情况 证券代码：301096 证券简称：百诚医药 公告编号：2025-029 杭州百诚医药科技股份有限公司 1、增持主体：楼金芳女士。本次增持前，楼金芳女士直接持有 ...

Core Insights - The hair medical concept sector has seen a rise of 2.25%, ranking third among concept sectors in terms of growth [1] - Within this sector, 11 stocks increased in value, with notable performers including Aoyang Health, Kanghui Pharmaceutical, and *ST Meigu, which reached their daily limit [1] - The sector experienced a net inflow of 64 million yuan from main funds, with Aoyang Health leading the inflow at 68.73 million yuan [2][3] Sector Performance - The hair medical concept sector's performance is highlighted by the following stocks: - Aoyang Health: increased by 10.12% with a turnover rate of 26.84% and a net inflow of 68.73 million yuan [3] - Taiankang: increased by 9.35% with a turnover rate of 10.42% and a net inflow of 51.69 million yuan [3] - Kanghui Pharmaceutical: increased by 9.99% with a turnover rate of 4.06% and a net inflow of 33.06 million yuan [3] - Huailong Co.: increased by 3.35% with a turnover rate of 11.07% and a net inflow of 14.87 million yuan [3] Fund Flow Analysis - The top stocks by net inflow ratio in the hair medical sector include: - Kanghui Pharmaceutical: net inflow ratio of 36.67% [3] - *ST Meigu: net inflow ratio of 11.74% [4] - Aoyang Health: net inflow ratio of 7.40% [3] - The overall trend indicates a strong interest from main funds in the hair medical sector, with several stocks showing significant inflows [2][3]

Group 1 - The hair medical concept sector increased by 3.82%, ranking fifth among concept sectors, with 18 stocks rising, including Aoyang Health which hit the daily limit, and Tainkang, Jiuzhitang, and Kangyuan Pharmaceutical showing significant gains of 13.80%, 5.79%, and 5.73% respectively [1][2] - The hair medical concept sector attracted a net inflow of 132 million yuan from main funds today, with 10 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan, led by Aoyang Health with a net inflow of 94.61 million yuan [2][3] - Aoyang Health, Nengte Technology, and Shuiyang Shares had the highest net inflow ratios, with 42.28%, 6.86%, and 6.82% respectively [3][4] Group 2 - The top stocks in the hair medical concept sector based on net inflow include Aoyang Health, Shuiyang Shares, and Langzi Shares, with respective net inflows of 94.61 million yuan, 53.93 million yuan, and 24.89 million yuan [2][3] - The trading performance of Aoyang Health showed a daily increase of 10.08% with a turnover rate of 7.13%, while other notable performers included Shuiyang Shares and Langzi Shares with increases of 4.22% and 3.10% respectively [3][4] - The overall market sentiment in the hair medical sector appears positive, as indicated by the significant inflows and stock performance [1][2]

Group 1 - The hair medical concept sector rose by 3.51%, ranking fifth among concept sectors, with 19 stocks increasing in value, including Langzi Co. and Jiuzhitang hitting the daily limit [1][2] - Notable gainers in the hair medical sector included Shuiyang Co. with a 12.74% increase, Baicheng Pharmaceutical at 7.06%, and Tainkang at 6.52% [1][2] Group 2 - The hair medical concept sector saw a net inflow of 201 million yuan from main funds, with 11 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflow [2] - Jiuzhitang led the net inflow with 133.5 million yuan, followed by Langzi Co. with 109 million yuan, and Zhendong Pharmaceutical with 27.87 million yuan [2][3] Group 3 - In terms of net inflow ratio, Langzi Co. and Jiuzhitang had the highest ratios at 25.49% and 23.83% respectively, while *ST Meigu had a ratio of 12.06% [3] - The hair medical concept sector's inflow ranking included Jiuzhitang, Langzi Co., Zhendong Pharmaceutical, and Baicheng Pharmaceutical, with respective daily price changes of 10.00%, 10.01%, 5.42%, and 7.06% [3]

Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]

Group 1: Company Overview and Operations - Baicheng Pharmaceutical has an international marketing department responsible for the export sales of active pharmaceutical ingredients and formulations [3] - The company is actively pursuing internationalization, with three active pharmaceutical ingredients (Minoxidil, Amorolfine, and Acetylcysteine) having submitted EU registration applications in 2024 [5] Group 2: Research and Development - In 2024, the company invested CNY 320 million in R&D, with plans to continue expanding R&D efforts [5] - The company has made significant progress in innovative drug development, having obtained two IND approvals for Class 1 new drugs and completed 11 IND submissions for Class 2 new drugs [6] - The company has 98 R&D projects with sales rights as of the end of 2024, of which 25 projects have been approved [6][7] Group 3: Financial Performance - The company reported a net loss of CNY 52,742,809.58 for the year 2024 [6] - Commercial production revenue for 2024 was CNY 36 million, attributed to the subsidiary, Saimer Pharmaceutical [6] Group 4: Strategic Focus - The company aims to balance R&D investment with short-term profitability by enhancing research efficiency and quality [4] - Future growth drivers include expanding the generic drug business, increasing innovative drug initiatives, and enhancing overseas market presence [6]